MedTrace Logo

Retrospective Evaluation of Lung Pathology in Subjects With COVID-19

NCT04878913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2024-09-04

No results posted yet for this study

Summary

Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial.

Conditions

Interventions

DRUG

C21

C21 was administered in the VP-C21-006 trial

DRUG

Placebo

Placebo was administered in the VP-C21-006 trial

Sponsors & Collaborators

  • Vicore Pharma AB

    lead INDUSTRY

Principal Investigators

  • Rohit Batta, MD · Vicore Pharma

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2021-08-23
Completion
2021-08-23

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04878913 on ClinicalTrials.gov